For information on  Beam-301 Gene Editing for the correction of the R83C mutation in GSD1a, by Beam Therapeutics, visit here.  

For information on the Moderna clinical trial of mRNA-3745 in patients with GSD1a, visit here.

For information on the Ultragenyx clinical trial of DTX401 in patients with GSDIa, visit here.

For information on the Ultragenyx clinical trial of UX053 in patients with GSD III, visit here

So, What Is GSD?


We are please to announce our volunteer committee members:

Dr. Sylvia Stockler
Dr. Michal Inbar-Feigenberg
Dr. John Mitchell
Dr. David Weinstein
Kathy Ross, RD
​Iris Ferrecchia, RN

Inform  Connect  Inspire

Canadian Association for Glycogen Storage Disease

The Canadian Organization for Glycogen Storage Disease (CanadianAGSD)  was created to help Canadian patients and their families affected with this rare disease.

Our purposes include:  providing individuals affected with GSD and their families with access to information about the disease, its consequences and potential therapies;  supporting research which contributes to the development of diagnostic tests and therapies (in Canada); and educating the health care community and the public about GSD; .  (All of our purposes can be found in the Overview section).

Your support is both needed and appreciated.  Our Board of Directors and Officers are volunteers.  Canadian AGSD is an official Canadian non profit that has charity status with Revenue Canada.

#CureGSD   #BeStrongStayStrong   #CanadianAGSD

Glycogen Storage Disease (Explained) 

Our friends at Scandinavian Association for Glycogen Storage Disease produced an informative documentary on the topic of GSD, including interviews with some of the world's leading GSD doctors.

It is an inspiring work. 

Congratulations,  Dr. Marcus Landgren and your SAGSD team!